Wegovy Patent Protection
17 patents · Novo Nordisk A/S
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 8536122 | Drug substance & product patent | Novo Nordisk A/S | Mar 20, 2026 | Expired |
| 8129343 | Drug substance & product patent | Novo Nordisk A/S | Dec 5, 2031 | 5.4y left |
| 9278123 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 11382957 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Dec 16, 2031 | 5.5y left |
| 11033499 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Jun 19, 2033 | 7.0y left |
| 9764003 | Orange Book listed patent | Novo Nordisk A/S | Jun 21, 2033 | 7.0y left |
| 12239739 | Orange Book listed patent | Novo Nordisk A/S | May 2, 2034 | 7.9y left |
| 10278923 | Orange Book listed patent | Novo Nordisk A/S | May 2, 2034 | 7.9y left |
| 12214017 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Aug 24, 2038 | 12.2y left |
| 11752198 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Aug 24, 2038 | 12.2y left |
| 10888605 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Aug 24, 2038 | 12.2y left |
| 12551536 | Orange Book listed patent | Novo Nordisk A/S | Oct 10, 2038 | 12.3y left |
| 12029779 | Orange Book listed patent | Novo Nordisk A/S | Oct 10, 2038 | 12.3y left |
| 12396953 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 1, 2039 | 12.6y left |
| 11833248 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 1, 2039 | 12.6y left |
| 11478533 | Orange Book listed patent | Novo Nordisk A/S | May 13, 2040 | 13.9y left |
| 11318191 | Drug product (formulation / method-of-use) patent | Novo Nordisk A/S | Feb 17, 2041 | 14.7y left |
Related Drug Patent Expirations
33 patents · earliest expires 2026 · Novo Nordisk A/S
17 patents · earliest expires 2026 · AstraZeneca AB
7 patents · earliest expires 2026 · Astellas Pharma Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
The Wegovy record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Wegovy sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Wegovy is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.